Dasatinib + Quercetin: How Far Along Is the Flagship Senolytic?

Dasatinib plus quercetin — usually written D+Q — is the closest thing senolytic medicine has to a flagship. When you read that "senolytics have been tested in humans," this is almost always the combination meant. It earned that status honestly: it was the first senolytic discovered through a deliberate mechanism-led search, the first given to people, and the first shown to actually reduce senescent cells in human tissue. But "furthest along" is not the same as "proven," and D+Q comes with a caveat the wellness framing tends to bury: it pairs a prescription leukemia chemotherapy drug with a plant flavonoid, and there is still no trial showing it extends human life or healthspan. This page lays out exactly how far the science has come — and how far it hasn't. For the wider map of what's earned its place versus what's hype, start with our pillar on longevity medicine: what's proven vs hyped.

What a senolytic is, and what D+Q actually is

As you age, some cells stop dividing but refuse to die — they become senescent. These "zombie cells" accumulate and secrete a soup of inflammatory signals (the senescence-associated secretory phenotype) that damages surrounding tissue. Cellular senescence is one of the formal hallmarks of aging⁸, and the leading review of the field lays out why clearing senescent cells is one of the most mechanistically compelling anti-aging strategies on the table⁷. A senolytic is a drug that selectively kills these senescent cells.

D+Q has two very different halves. Dasatinib is an FDA-approved tyrosine-kinase-inhibitor chemotherapy drug, used to treat certain leukemias — a real prescription medicine with real side effects and a serious safety profile, not a supplement. Quercetin is a flavonoid found in foods like onions and apples, sold over the counter as a supplement. The senolytic insight was that the two together hit the survival pathways senescent cells depend on more effectively than either alone — which is exactly how the combination was found.

The discovery and the mouse data: a genuine foundation

D+Q's credibility is earned, not hype. The 2015 paper that launched the field identified senescent cells' "Achilles' heel" — the pro-survival networks they rely on — and used that map to pick dasatinib and quercetin as the first targeted senolytic drugs¹. The landmark follow-up in mice went further: intermittent senolytic treatment in aged animals improved physical function and increased lifespan, even when started late in life². That combination — a rational mechanism plus a real mouse lifespan result with intermittent "hit-and-run" dosing — is what makes senolytics one of the few genuinely serious anti-aging strategies rather than another supplement story.

But it remains, at the lifespan level, mouse data. A drug that extends life in mice is a hypothesis about people, not a result in them — and rodent lifespan extensions translate to humans far less often than headlines imply.

The human trials: real proof-of-concept, but small and not about lifespan

Here is what makes D+Q the flagship — and where the honesty has to come in. There genuinely is human D+Q trial data, and it matters:

First-in-human, idiopathic pulmonary fibrosis (2019). An open-label pilot in 14 patients with IPF — a brutal, fatal lung-scarring disease with substantial senescent-cell involvement — reported that D+Q improved some physical-function measures (like walking-test performance)³. It was tiny and uncontrolled, but it was the first time senolytics were given to humans at all.

Diabetic kidney disease (2019). A separate small trial did something even more important: it showed D+Q measurably reduced the burden of senescent cells in human fat and skin tissue⁴. This was the first direct human evidence that senolytics actually do what they're supposed to do in people — clear zombie cells — not just in a dish or a mouse. As proof-of-concept for the senolytic mechanism, it's a landmark.

Alzheimer's disease (2023). A phase 1 feasibility trial established that D+Q could be given to people with mild Alzheimer's, that the drugs reached the brain, and that the approach was tolerable enough to justify larger studies — explicitly a safety/feasibility step, not an efficacy result⁵.

Cognition and mobility in older adults (2025). A more recent pilot tested D+Q to improve cognition and mobility in older adults at risk of decline; like the others, it's a small early-stage study generating signals to test further, not a definitive outcome trial⁶.

Notice the pattern. Every one of these is small, mostly early-phase, and measures senescent-cell markers, feasibility, or short-term function in sick or at-risk patients — not lifespan, not healthspan, and not aging in healthy people. They prove the senolytic concept has legs in humans. They do not prove D+Q makes people age slower or live longer, and no trial has been designed yet that could.

The drug-status reality the wellness pitch skips

This is the most important practical point, and the one online sellers and biohacking forums gloss over: dasatinib is chemotherapy. It's a prescription tyrosine-kinase inhibitor approved for leukemia, with a side-effect profile that includes serious risks (fluid retention around the lungs and heart, bleeding, low blood counts, cardiac effects) — the things you'd expect from a cancer drug. Using it off-label as a "longevity" intervention means taking a serious medicine outside its approved indication, in a regimen whose long-term safety in healthy aging people is completely unestablished. Quercetin is a benign supplement; dasatinib is not, and the combination's risk is driven by the dasatinib half. Anyone treating D+Q like a stack of two supplements has misunderstood what it is. This is precisely the kind of intervention that belongs under genuine physician supervision — see what a longevity doctor actually does for the difference real clinical oversight makes — not self-sourced from a grey-market vendor.

On top of the drug-safety issue: the "hit-and-run" intermittent schedules used in trials (a few days, periodically) are research protocols, and the optimal dose, interval, and whether any durable benefit results in humans are all unsettled. "Tolerated in a small short trial of patients" is not "proven safe for years of self-directed anti-aging use."

The grade

The bottom line

Dasatinib plus quercetin is the most advanced senolytic in human research, and that status is deserved: it was the first senolytic discovered by design, the first given to people, and the first shown to clear senescent cells in human tissue, on top of a real mouse lifespan result. That's a serious, legitimate research program — genuinely one of the more promising directions in aging biology. But "furthest along" still means early. The human trials are small, mostly early-phase, and measure senescent-cell markers, feasibility, and short-term function in sick or at-risk patients — never lifespan or healthspan, and never in healthy people. And the intervention is not a supplement stack: it pairs a flavonoid with a prescription leukemia chemotherapy drug whose off-label long-term safety in aging adults is unknown. D+Q is the best evidence the senolytic concept works in humans, and simultaneously an experimental, doctor's-supervision-required intervention that has not been shown to extend human life. Promising, important — and not ready to self-administer. For how senolytics sit alongside the rest of the field's experimental tools, see peptides for longevity, and for programs with real clinical oversight, our graded best longevity clinics hub.